MLAB · Mesa Laboratories, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on MLAB. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About MLAB · Mesa Laboratories, Inc.
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Live Quote
HOLD (score +0) · 12-1 mom 10.7% · RSI 37.1 · above_200_only · -15.7% from high
Targets blend Wall Street consensus (2 analysts: low $94.00 / mean $112.00 / high $130.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
The investigation triggered on a cluster of 3 Form 4 filings in the last 14 days — but ALL THREE were S-code (sell) transactions: CFO John Sakys sold $123K (RSU tax withholding), CAO Lyndsey Crennen sold ~$12K, and SVP Brian Archbold sold ~$117K, all from RSU vest dates on June 15. These are not open-market purchases; they are routine corporate tax-withholding events with zero directional signal. The broader Form 4 record shows genuine director buys in March 2026 at $72-76 (Ladiwala, Capone, Tripeny), but no CEO/CFO/COO-level P-code (purchase) transactions anywhere in the recent window. Fundamentally MLAB is a small-cap ($524M EV) life sciences tools company with flat revenue growth (2.6% YoY), very low ROIC (~3%), and significant leverage (net debt/EBITDA ~5x). The stock has pulled back from its 52-week high of $113.99 to $94.76, down ~17%, after a Q4 FY26 earnings miss on May 27, 2026 that triggered a large sell-off. At forward P/E of ~7.7x the company appears cheap relative to life sciences tools peers — but the low multiple reflects real structural concerns (Clinical Genomics headwinds, high leverage, margin pressure). Options data is unavailable (no listed expiries), eliminating income strategy viability. Given the absence of a genuine mispricing edge, no meaningful near-term catalyst beyond earnings on August 5, and heavy insider selling at current depressed levels, there is no actionable asymmetric setup here.